Passage Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
Passage Bio, Inc. filed a Form 8-K reporting the results of its 2023 Annual Meeting of Stockholders held on May 25, 2023. The company is incorporated in Delaware and its common stock trades on Nasdaq under the symbol PASG.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial results. It identifies KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Material Changes and Meeting Results
- Stockholders elected three Class III directors for three-year terms expiring at the 2026 annual meeting: Athena Countouriotis, M.D., Saqib Islam, and Sandip Kapadia.
- Votes for the director nominees were 28,649,239, 24,225,087, and 27,401,976, respectively. Each nominee also received 6,239,108 broker non-votes.
- Stockholders ratified KPMG LLP as the company’s independent registered public accounting firm for fiscal 2023: 37,654,833 votes for, 279,241 against, and 43,947 abstaining.
- Stockholders approved an amendment and restatement of the company’s amended and restated certificate of incorporation to permit exculpation of company officers from personal liability for certain breaches of the duty of care: 30,135,810 votes for, 1,536,404 against, 66,699 abstaining, and 6,239,108 broker non-votes.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, business outlook, management commentary, contingencies, or risk updates. The approved charter amendment concerns officer liability protections and does not provide details in this filing regarding its practical application or scope beyond certain breaches of the duty of care.
Important Facts to Verify
- Confirm the elected directors’ terms and subsequent board composition.
- Review the amended and restated certificate of incorporation for the precise officer exculpation provisions.
- Review subsequent filings for any changes in KPMG’s appointment or audit status.
- Use the company’s periodic reports, rather than this 8-K, to verify financial performance, cash runway, debt, liquidity, and clinical or commercial developments.